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Adoptive cell transfer using engineered T cells is emerging as a promising treatment fo
metastatic melanoma. Such an approach allows one to introduce T cell receptor (TCR
modifications that, while maintaining the specificity for the targeted antigen, can enhanc
the binding and kinetic parameters for the interaction with peptides (p) bound to majo
histocompatibility complexes (MHC). Using the well-characterized 2C TCR/SIYR/H-2K(b
structure as a model system, we demonstrated that a binding free energy decompo
sition based on the MM-GBSA approach provides a detailed and reliable description o
the TCR/pMHC interactions at the structural and thermodynamic levels. Starting fro
this result, we developed a new structure-based approach, to rationally design new TC
sequences, and applied it to the BC1TCR targeting the HLA-A2 restricted NY-ESO-1157–16
cancer-testis epitope. Fifty-four percent of the designed sequence replacements exhibite
improved pMHC binding as compared to the native TCR, with up to 150-fold increase i
affinity, while preserving specificity. Genetically engineered CD8+T cells expressing thes
modifiedTCRs showed an improved functional activity compared to those expressing BC
TCR. We measured maximum levels of activities for TCRs within the upper limit of nat
ural affinity, K D=∼1−5µM. Beyond the affinity threshold at K D <1µM we observe
an attenuation in cellular function, in line with the “half-life” model of T cell activation
Our computer-aided protein-engineering approach requires the 3D-structure of the TCR
pMHC complex of interest, which can be obtained from X-ray crystallography. We hav
also developed a homology modeling-based approach,TCRep 3D, to obtain accurate struc
tural models of any TCR-pMHC complexes when experimental data is not available. Sinc
the accuracy of the models depends on the prediction of the TCR orientation over pMHC
we have complemented the approach with a simplified rigid method to predict this orien
tation and successfully assessed it using all non-redundant TCR-pMHC crystal structure
available. These methods potentially extend the use of our TCR engineering method t
entire TCR repertoires for which no X-ray structure is available. We have also performe
a steered molecular dynamics study of the unbinding of the TCR-pMHC complex to ge
a better understanding of how TCRs interact with pMHCs. This entire rational TCR desig
pipeline is now being used to produce rationally optimizedTCRs for adoptive cell therapie
of stage IV melanoma.
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INTRODUCTION
Recognition by the CD8+ T cell receptor (TCR) of immunogenic
peptide (p) presented by class I major histocompatibility com-
plexes (MHC) is a key event in the specific immune response
against virus-infected cells or tumor cells. Binding of the TCR to
the pMHC complex leads to T cell activation and killing of the
target cell (1). The TCR is composed of two chains, α and β, that
pair on the surface of the T cell to form a heterodimeric receptor
on the surface of the T cell. Each chain is composed of a con-
stant domain that anchors the protein in the cell membrane and
of a variable domain that confers antigen recognition (Figure 1).
The TCR contacts pMHC molecules via the 6 complementarity-
determining regions (CDR), three each from the α and β chains
(Figure 2). These CDRs constitute the hypervariable regions of
the two V domains, called Vα and Vβ (2–4). They are generated by
somatic gene rearrangement and negatively selected in the thymus
against reactivity with endogenic pMHCs. CDR3α and CDR3β
are the most diverse regions of the TCR and thus play a major role
in antigen specificity. The CDR1 and CDR2 loops of the α and
β chains predominantly make contact with the MHC molecule.
The strength of the interaction between TCR and pMHC has been
shown to play an important role in the T cell activation (5–9).
However, the kinetics of the TCR/pMHC interaction is also deter-
minant in T cell activation (10, 11). Consequently, understanding
the biophysical properties of the TCR/pMHC interaction is of
great interest for the prediction of the T cell activation, and for
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FIGURE 1 | 3D-structure of theTCR-pMHC complex. (1G4 TCR bound to
NY-ESO-1/HLA-A201, entry 2BNR (124) of the PDB). TCRα, TCRβ, MHC, and
b2-microglobulin are colored in blue, cyan, orange, and green, respectively.
The NY-ESO-1 peptide is displayed in ball and stick.
FIGURE 2 | Position of theTCR CDRs over the pMHC surface. CDR1s,
CDR2s, and CDR3s are colored in magenta, green, and red, respectively.
the rational TCR optimization toward improved adoptive transfer
cancer therapy (12, 13).
This review will focus on the different computer-aided tech-
niques we developed and used to study the TCR-pMHC complex
from a structural and thermodynamic point of view. First we
present the results obtained by steered molecular dynamics (SMD)
simulations of molecular recognition events occurring during the
TCR-pMHC complex formation. Second, we describe the different
approaches we developed to derive structural models of TCR-
pMHC complexes for a large TCR repertoire. Third, we summarize
our approaches to estimate the binding free energy for the TCR
association to pMHC. Finally, we present our in silico structure-
based protein-engineering approach that enables the fine-tuning
of TCR-pMHC binding parameters.
INVESTIGATING TCR-pMHC INTERACTIONS USING STEERED
MD SIMULATIONS
The structure of ∼66 TCR-pMHC complexes are known to date
(14) among which ∼25 are unique complexes. The compared
features of these structures were the object of extensive reviews
(1, 15, 16). In addition, binding kinetics and thermodynamics of
many complexes have been measured (17). The general picture
that emerges is that T cell activation requires TCR-pMHC binding
to fall within a certain range of affinity and kinetics. However, clear
structural determinants of TCR specificity have remained elusive.
A single mutation can change a peptide from agonist to antagonist,
but the same TCR can recognize various peptides with different
binding modes. Thus TCRs can be exquisitely specific while dis-
playing a high degree of cross-reactivity. In addition, TCRs use
extremely varied thermodynamic strategies to bind to pMHCs,
ranging from entropy-favored to entropy-opposed.
A system that exemplifies both the sensitivity of TCR recog-
nition and its potential for cross-reactivity with different binding
strategies is the Tax nonapeptide (LLFGYPVYV) from the HTLV-1
virus presented by the HLA-A0201 MHC. This pMHC is a strong
agonist for the A6 TCR but the P6A peptide mutant (Pro replaced
by Ala at position 6, see Figure 3A) dramatically reduces the bind-
ing affinity and abrogates T cell activation (18). On the other
hand, the B7 TCR, which has the same α chain as A6 but a dif-
ferent β chain, is also activated by the Tax peptide presented by
the same MHC. B7 binds with an affinity similar to A6, but the
binding is entropically opposed, whereas A6 binding is entropi-
cally favored, outlining a completely different binding mechanism
(19) (see Figure 3B).
Detailed aspects of protein–protein interactions can be charac-
terized by SMD simulations, in which the dissociation is actuated
by an external force acting on the protein. A typical reaction coor-
dinate for protein–protein dissociation is the distance between the
centers of mass of each protein. In the following, we call this reac-
tion coordinate ξ. In the case of the TCR-pMHC, we assumed that
the dissociation happens in the direction perpendicular to the cel-
lular membranes (see Figure 3C). We also assumed that there is
no substantial conformational rearrangement upon dissociation
(except possibly in the CDRs and in the peptide), which is sup-
ported by the similarity of X-ray structures of bound and unbound
TCRs or pMHCs. To enforce these assumptions during the SMD,
we devised the individual pulling scheme (20) in which each non-
H atom (except CDRs and peptide) is subjected to an individual
harmonic potential. As shown on Figure 3D, the center of mass
distance ξ is increased by collectively shifting the reference posi-
tions of the individual potentials. For each TCR-pMHC complex,
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FIGURE 3 | (A) The A6 TCR (yellow and orange) bound to the HLA-A2
MHC (blue) presenting the Tax peptide (cyan). The P6A peptide mutant is
overlaid in magenta (PDB entry 1AO7). The site of the P6A mutation is
indicated by a red arrow. (B) Experimental TCR binding thermodynamics.
For P6A-A6, no entropy/enthalpy measurements are available. References
are given in the text. (C) TCR-pMHC complex in its simulation box before
and after the SMD simulation (water molecules not shown). (D) The
individual pulling scheme used to dissociate the proteins. The distance ξ
between the centers of mass is increased at rate 2v. Each backbone
heavy atom is subjected to an individual harmonic potential. All individual
potentials move in concert, with their relative positions fixed to their
values in the crystal structure.
we performed about 150 unbinding trajectories of 4 ns each dur-
ing which ξ is gradually increased by 2 nm from the bound state
distance to reach a final conformation as shown on the right panel
of Figure 3C. The simulations were performed with the Gromacs
software (21) using the Gromos 45a3 force field (22) with explicit
water molecules.
With about 150 trajectories we were able to obtain converged
ensemble averages of many observables at any given protein–
protein separation, including for highly fluctuating quantities
involving solvent molecules. In particular, we established maps
of H-bonds or of non-polar contacts for all residues of the TCR
and pMHC as a function of ξ. As an example, Figure 4B shows an
H-bond occurrence map for the OH group on the Tyr5 side-chain
of the Tax peptide in the Tax-A6 system. We see that α-S31 is the
main TCR H-bonding partner in the bound state, but that new H-
bonds are formed with α-S100 in the transition state. Overall, our
simulations have shown that the number and diversity of H-bonds
occurring in a protein complex largely exceeds what is appar-
ent from the crystal structures. Using this methodology, detailed
maps such as Figure 4B can be established for any interaction to
any atom in the system, depending on the biological question of
interest.
For all three TCR-pMHC complexes,we monitored energy vari-
ations in different parts of the system upon dissociation. Figure 4C
shows that there are differences in TCR-pMHC interaction ener-
gies between the complexes. But these are largely compensated by
effects in the internal protein reorganization energy (Figure 4D),
solvent-protein interaction energy (Figure 4E), and solvent inter-
nal energy (Figure 4F). As a general lesson for protein–protein
interactions, we retain that the solvent plays a key role in two
different ways. First, variations of solvation energies exceed con-
tributions from the proteins themselves upon binding. Second,
specific water molecules trapped at the interface can influence the
binding mechanism and thermodynamics (data not shown). In the
present case, these two aspects happen to be also the two major
factors differentiating A6 and B7 binding.
Focusing on the bound state of the TCR-pMHC complexes, the
decomposition of the average interaction energy among CDRs
brings valuable insights. Figure 4A illustrates the differences
between the A6 and B7 binding modes, with a much less prominent
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FIGURE 4 | Results from the SMD dissociation of threeTCR-pMHC
complexes. (A) Average interaction energy in the bound complexes,
partitioned in CDR and peptide/MHC contributions. (B) Focus on the
OH group on the side-chain of the peptide Tyr 5 residue. The color bars
indicate the average occurrence of H-bonds with TCR atoms as a
function of center of mass separation ξ. Red means that the H-bond is
formed almost all the time, blue indicate a rare interaction.
(C) Interaction energy between the TCR and the pMHC for all three
complexes, as a function of ξ. (D) Total internal energy (bonded and
non-bonded) of TCR and pMHC. (E) Solvent-protein interaction energy.
(F) Solvent internal energy. The contributions from (C–F) add up to the
total system energy.
contribution of CDR3α for B7. Generally for all complexes,
Figure 4A shows that, while CDR2 interacts mostly with MHC,
both CDR1 and CDR3 interact equally with peptide and MHC,
even at large distance, as confirmed by our H-bond occurrence
maps (not shown). Therefore, our simulations do not support the
two-step model (23) for TCR engagement, in which the CDR1 and
CDR2 preferentially contact the MHC at large distance, while the
CDR3 establishes final contacts to “read” the peptide mainly at
short distances.
Overall, although the P6A-A6 complex has a very different
affinity compared to the wild-type Tax-A6, both complexes share
very similar features in terms of specific H-bonds or energy con-
tributions. On the other hand, the Tax-B7 complex has a binding
affinity similar to that of Tax-A6, but uses a completely different
binding mechanism. The B7 TCR creates a very different set of H-
bonds and hydrophobic contacts to the pMHC and makes a very
different usage of the solvent, which reflects in a different partition
of the binding energy. In retrospect, as noted previously by Baker
and coworkers (24), it is not so surprising to observe active TCRs
with very different binding mechanisms. Indeed, if TCRs are issued
from random sequence variation and selection upon pMHC bind-
ing affinity and kinetics only, each TCR is likely to adopt its own
unique pMHC binding strategy as long as it matches these criteria.
TCR-pMHC HOMOLOGY MODELING
PIONEERING STUDY OF TCR-pMHC HOMOLOGY MODELING
The recent development and use of experimental techniques to
determine sequences of TCRs that bind to a pMHC complex (25),
led to the collection of large repertoires of TCR sequences with
given pMHC specificities (26, 27). Understanding the selection
mechanism that causes this gene usage can be facilitated by the
introduction of structural information regarding the underlying
TCR-pMHC complexes. This information can be used to identify
conserved 3D binding motifs that are not obvious from reper-
toire sequences alone (28), to suggest explanations regarding the
impact of TCR mutation on its affinity for given pMHCs (29) and
ultimately to support the rational engineering of TCRs with partic-
ular binding properties (7,30). Experimental structural techniques
such as X-ray crystallography or NMR provide direct and valu-
able information regarding the 3D-structures of macromolecules.
Unfortunately, they require the production of the protein, can be
time consuming, and are thus hardly applicable to the analysis
of large repertoires of tens to hundreds of TCRs. According to
the 3D-structure database of the international ImMunoGenetics
information system [IMGT/3D-structure-DB (31, 32)] the 3D-
structure of 66 TCR-pMHC complexes have been determined
experimentally so far. This number is negligible compared to the
vast TCR diversity created by genetic rearrangements of the TCR
V, D, and J genes. Indeed, the number of unique TCRβ chains
in blood has been estimated to be of the order of 106 (33, 34).
There is thus a need for tools able to predict the 3D-structure of
TCR-pMHC complexes from the amino acid sequences of their
components.
The pioneering work of Michielin et al. (29) provided a remark-
able demonstration of the feasibility and the predictive ability of
TCR-pMHC 3D-structure modeling. The authors used a murine
Frontiers in Immunology | T Cell Biology September 2013 | Volume 4 | Article 268 | 4
Zoete et al. Structure-based, rational design of T cell receptors
T1 TCR, specific for a photoreactive derivative of the Plasmodium
berghei circumsporozoite (PbCS) 253–260 nonapeptide presented
by the K D class I MHC (35). Fifty mutants involving the TCR’s
CDR, the MHC’s α1 and α2 helices and the peptide were prepared
and the association constants between the TCR and the pMHC
were measured (35). A first homology model was built for the
wild-type TCR-pMHC complex with the MODELLER program
(36–38), using the four TCR structures available at that time (39–
42) and the structure of H-2Kb MHC (43) as templates. These
structures provided good templates for the β-sheet framework
of the TCR, and of the α helices/β-sheet of the MHC grooves.
The high secondary structure content of these regions imposed
strong restrictions on their backbone conformation according to
the MODELLER algorithm, which facilitates the modeling of those
parts. In contrast, the CDR loops of TCRs have a very low level of
sequence identity and no specific secondary structure, which obvi-
ously limits the efficiency of modeling by homology. The CDR
loops conformation obtained in the first homology model were
thus refined using a simulated annealing technique (44), followed
by clustering the generated conformations based on their rela-
tive Cartesian coordinate root mean square deviation (RMSD). A
final conformation was chosen from a well-populated, low-energy
cluster, whose structure was compatible with the experimental
mutational data. All but three of the 50 mutations found qualita-
tive explanation in the model in terms of breaking of a significant
TCR/pMHC interaction. In addition, the model suggested that a
TCR pocket could form upon binding to accommodate the pep-
tide hapten, explaining the high level of affinity of the T1 TCR for
this pMHC (K D∼ 10 nM), and demonstrating predictive capabil-
ities for the modeling approach that go beyond reproducing only
the structural features present in the templates. Since more X-ray
structures of TCR-ligand complexes are continuously determined,
it could be expected that the range of applicability and the accu-
racy of such a modeling approach would improve, since there is
no limitation to the number of simultaneous templates that can
be used.
TCRep 3D
The first study described above (29) led to the development
of TCRep 3D, as a generalization of the TCR-pMHC model-
ing approach (28). TCRep 3D is an approach dedicated to the
prediction of high-quality 3D-structures that can provide a func-
tional insight on the interaction between a TCR and a pMHC.
It includes by design minimal input and optimal automation, to
analyze wide sets of sequences of TCRs belonging to a common
TCR repertoire.
The modeling pipeline is composed of two modules (see
Figure 5): (i) homology modeling of the TCR-pMHC complex
and (ii) ab initio CDR loops structure optimization. First, the user
provides the sequence of the target complex and a list of preferred
templates. By default, all the TCR-pMHC templates of the Pro-
tein Data Bank are used. The global structure of the complex is
modeled by homology. It could be possible to couple this step
to computer-aided approaches for the docking of peptide anti-
gens into MHC molecules (45), in case the peptide binding mode
could not be correctly predicted by homology modeling. Each
CDR loop is then subsequently refined while the rest of the com-
plex remains rigid. The MODELLER (38) software is used for the
two modules.
The originality of TCRep 3D resides in the specific bias that we
impose to the system during the structural sampling. Canonical
restraints available from the literature (46) are added to the back-
bone dihedral angles of CDR1 and 2 to limit the conformational
space accessible to the loops. We developed an iterative sampling
FIGURE 5 | Key steps of theTCRep 3D modeling procedure.
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method that identifies potential hydrogen bonds between TCR and
pMHC, and converts them into modeling restraints. The scoring
function was adapted accordingly, to favor structures that satisfy
most of the canonical restraints, and display potential hydrogen
bonds. We demonstrated that TCRep 3D is significantly more effi-
cient than common loop modeling approaches in predicting CDR
loops conformations.
At the time of the study, TCRep 3D produced one TCR-pMHC
structure in 7 days on a single CPU. However, the modeling can
be parallelized on a computing grid, and the computation time
scales efficiently with the number of CPUs used, allowing the user
to quickly model a large number of sequences.
TCRep 3D has been successfully applied to experimentally
determined sets of sequences of TCRs that recognize given cancer
epitopes.
(a) In a study on HLA-A∗0201/Melan-A-specific CD8 T cells (47),
the modeling of the TCR-pMHC 3D-structure revealed the
structural feature that explained how two distinct sets of TCR
performed differently in recognizing a naturally occurring
decamer variant of the Melan-A peptide. One of the TCR
subsets could not make proper interactions with the glutamic
acid at position 1 of the peptide because of the location and
structural properties of the CDR1α (see Figures 6A,B).
(b) The analysis of HLA-A∗0201/NY-ESO-1157–165 specific CD8+
T cells from five melanoma patients showed a preferential
usage of three Vβ genes. Additionally, experimental evidence
on the importance of the Met4-Trp5 pair of the NY-ESO-
1157–165 antigen were found, suggesting that those two contact
residues make critical interactions with the TCR, regardless of
the gene segment usage (26). The modeling of the correspond-
ing TCR-pMHC structures revealed a striking mechanism of
selection through the presence of a single conserved glycine
residue situated in the center of all CDR3β. An in vitro exper-
imental functional study of mutations of this amino acid
combined with in silico modeling of several mutants was per-
formed. All mutations resulted in dramatic structural changes
associated with complete experimental loss of affinity of the
TCR to NY-ESO-1/HLA-A∗0201 (28).
LONG-RANGE DRIVING FORCE FOR TCR ORIENTATION
Over the years, successive releases of TCR-pMHC crystal structures
have revealed the variety of native binding orientations that the
TCR can adopt. Recent studies reported a range of more than 45°
in the TCR binding angles relative to the MHC (48), depending on
the peptide, the MHC, and the α/β pairing of the TCR. Although
the challenge of TCR binding mode prediction has been recur-
rently discussed, only a few studies have focused on predicting the
actual binding mode of given TCR-pMHC (49, 50). Therefore, all
methods and applications relied on the existence of at least one
TCR-pMHC crystal structure.
In order to understand the molecular basis that governs TCR
orientation upon binding, we tested a simplified rigid approach on
all published TCR-pMHC crystal structures (48), which allowed
scanning quickly multiple orientations of the TCR relative to the
pMHC. In this approach, the TCR was moved 6–12 Å away from
the pMHC molecule along the TCR principal axis (see Figure 7A).
Subsequently, the TCR was rotated around that same axis until a
complete revolution was obtained (see Figure 7B). The effective
energy of the system was computed every 5°, as the sum of the
intermolecular energy and the solvation free energy, using the
CHARMM22 force field (51, 52) in combination with the FACTS
implicit solvation model (53).
We demonstrated that the sum of the Coulomb interaction
and the electrostatic solvation energies is sufficient to identify the
native TCR orientation as the energetic minimum upon rotation
(see Figure 7C). Importantly, despite the rigid-body simplifica-
tion, the results were robust upon small structural variations of the
TCR such as changes induced by MD simulations. We also tested
our approach on crystal structures of unbound TCRs, which were
confronted to pMHCs. Accurate energy minima were also identi-
fied, suggesting that perfect shape complementarity is not required
to obtain a reliable signal. The long-distance interactions during
the TCR approach appear to be independent of the binding process
itself, since the binding orientation is reliably identified without
considering either short-range energy terms or CDR induced fit
upon binding.
Furthermore, we decomposed the effective energy into per-
residue contributions, in an approach that is similar to the
FIGURE 6 | (A) Structural differences between nona- vs. decamer-specific TCR bound to Melan-A(ELA)/HLA− A∗0201. The green line identifies the hydrogen
bond that is formed between CDR1α and Glu1 of the peptide. No favorable interactions were identified between M77-80 and the decamer variant of Melan-A.
(B) In silico mutation results in NY-ESO-1 repertoire. The dramatic structural rearrangement of the mutated CDR3β confirms the importance of the central Gly.
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FIGURE 7 | Rigid displacement protocol. (A) Rigid TCR translation along the principal axis. (B) Rigid TCR rotation around the principal axis. (C) Landscape
representation of the TCR-pMHC polar energy as a function of the TCR/pMHC distance and the TCR angle. 0° corresponds to the native orientation of the bound
conformation.
Molecular Mechanics – Generalized Born Surface Area (MM-
GBSA) energy decompositions (54). The contributions of struc-
tural sub-groups to the profile of the TCR/pMHC interaction
energy during rotation were calculated, to estimate their role in
the overall orientation. Results showed that most of the driving
force (>90%) leading to the orientation of the TCR is defined
by CDR1,2/MHC interactions. This is in agreement with pre-
vious observations, revealing a ring of charged residues at the
pMHC interface, which interacts with CDR1,2 with complemen-
tary charges (48). We reported that the role of the CDR3/peptide
interaction is of lesser importance at long-distance.
In turn, such knowledge of the structure may be used as a
preliminary approach in the process of modeling protein/protein
interactions. More specifically, the rigid search for an energetic
minimum upon TCR rotation may become a complementary
module of TCRep 3D, to search for the correct binding mode, after
modeling the TCR and the pMHC independently. We attempted
to predict the binding mode of the A6 TCR with tax/HLA-A∗0201,
after modeling the TCR by homology. The effective energy min-
imum upon rotation was computed for 500 homology models,
and we obtained an average shift of 12.2° from the orientation
of the crystal structure. This demonstrated the potential of the
approach as a component of a TCR-pMHC structural prediction
pipeline (55). The approach is also easily applicable to other types
of protein complexes, provided that the association is also driven
by long-range electrostatic interactions.
FREE ENERGY CALCULATIONS
APPLICATION OF THE THERMODYNAMIC INTEGRATION METHOD FOR
TCR-pMHC BINDING FREE ENERGY DIFFERENCES
T cell receptor recognition can exhibit exquisite specificity upon
single peptide mutation. In the A6/Tax/HLA-A0201 complex
described above (Tax-A6), mutating the Ala at position 6 to
a Pro (P6A) turns the Tax peptide from a strong agonist
into a weak antagonist. These systems were extensively studied
experimentally (18, 56) and the binding free energy difference
between the Tax-A6 and the P6A-A6 complexes was found to
be ∆∆G= 2.90± 0.20 kcal/mol. (see Figure 3B). These results
are difficult to rationalize from the structure alone, as there is
almost no difference between the conformations of the Tax-A6
and P6A-A6 complexes (see Figure 3A, red arrow). To gain a better
understanding of the effect of the mutation on TCR recognition,
we used free energy simulation to analyze in detail the origin of
the binding free energy difference (57).
As we will see below, calculating the binding free energy by sim-
ulating the entire TCR-pMHC unbinding process itself is difficult.
Instead, the present method uses the thermodynamic cycle shown
in Figure 8A to reformulate the problem,
∆∆G
Binding
P6A = ∆GBindingP6 −∆GBindingA6 = ∆GP6→A6Bound −∆GP6→A6Unbound.
(1)
This means that we can obtain ∆∆G
Binding
P6A by computing the
P6→A6 mutation free energy in both the unbound and the bound
states. Among the different methods available to calculate muta-
tion free energy differences (58, 59), we chose thermodynamic
integration (60, 61). We define an interpolated potential energy
function U (r, λ) that is equivalent to the potential energy func-
tion of the wild-type forλ= 0 (Pro) and to that of the P6A mutant
forλ= 1 (Ala). The free energy difference can be obtained through
∆GP6→A6Bound =
∫ 1
0
〈
∂U (r ,λ)
∂λ
〉
λ
dλ.
Here, 〈·〉λ represents an ensemble average at fixed λ. In prac-
tice, we perform a set of simulations at discrete λ-values and
evaluate the integral above numerically. The number and posi-
tion of λ-values required for accurate integration depends on the
smoothness of the
〈
∂U
∂λ
〉
λ
function. To construct an appropriate
interpolating potential energy function, a dual topology scheme
was used, as shown on Figure 8B. For vanishing atoms, only the
non-bonded interactions are scaled, while the bonded interactions
are left unchanged (62). As we did not use soft-core potentials
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FIGURE 8 | (A) The thermodynamic cycle underlying Eq. 1. (B) The dual
topology scheme used to interpolate the potential energy function between
the Pro side-chain (green) and the Ala side-chain (blue). Common atoms are
unaffected, Duplicated atoms change type and non-bonded parameters.
Unique atoms vanish, with their non-bonded interactions switched to zero
and their bonded interactions unchanged. (C) Derivatives of the free energy
obtained for each λ-value in three independent runs for the bound complex.
(D) Idem for the unbound complex.
(63) for vanishing atoms, special care was taken in the limit of
λ→ 0 and λ→ 1 to deal with the singularities of the Coulomb
and Lennard-Jones potentials.
Starting from the crystal structures for both the unbound (64)
and the bound complex (18), MD simulations were performed in
the CHARMM program (51) with the CHARMM22 force field
(52). The proteins were locally solvated in a sphere of 16 Å sur-
rounding the peptide using the stochastic boundary method (65).
The set of λ-values used were λ= 0.02, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6,
0.7, 0.8, 0.9, 0.98. After 100 ps of initial equilibration, data was
collected for 30 ps at each λ-value, separated by 10 ps equilibra-
tion time after eachλ update. Three simulations with independent
initial velocities were produced.
The simulations were structurally stable with average RMSD
of non-H atoms no greater than 0.8 Å with respect to the crys-
tal structures. The average free energy derivatives obtained in the
three different runs are shown on Figures 8C,D for the bound and
unbound states, respectively. In the unbound state (Figure 8D),
the derivative takes very large values close to λ= 1, due to the
interaction of the vanishing Pro atoms with the solvent molecules.
This does not happen in the bound state, because the vanishing
atoms are concealed from the solvent in the void created by the
protein pocket.
Three different schemes were tested for the extrapolation to
λ= 0 and λ= 1, using linear, quadratic or λ−3/4 functions. The
integration over all λ-values was performed using the trape-
zoidal rule. The final result is ∆∆G
Binding
P6A = 2.9 ± 1.1 kcal/mol,
which compares very favorably with the experimental value of
2.9± 0.2 kcal/mol.
One of the major strengths of the method lies in the linearity
of Eq. 1, which allows decomposing as a sum of contributions
form different types of interactions and/or of different parts of
the system. Given that the total free energy difference is in good
agreement with experiment, there is a good chance that the decom-
position provides meaningful insights on the mechanisms leading
to TCR specificity.
A notable contribution to ∆∆G (+0.64 kcal/mol) arises from
the difference in solvation free energy of the mutated residue:
in the unbound structure, the Tax P6 residue is solvent-exposed
with around 35% of its surface accessible to water molecules.
The A6 mutant has fewer exposed hydrophobic groups, which
entails a more modest solvation penalty in the unbound state.
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This stabilizes the unbound state of the P6A mutant relative to the
wild-type, which in turn makes P6A-A6 binding less favorable The
rest of the peptide contributes a modest 0.38 kcal/mol to ∆∆G.
The total contribution of the TCR in the bound state is around
+0.8 kcal/mol destabilizing the P6A mutant, the most significant
part of which is due to the CDR3α loop. Most of this energy arises
from the van der Waals term, in accord with the fact that the TCR
provides good surface complementarity for the hydrophobic side-
chain of the Pro residue. Since the pocket is already present in
the Tax-A6 complex, there is no large free energy cost needed to
induce it, in contrast to what is found in the solvent. The TCR
residues that contribute the most to the TCR specificity for the
wild-type peptide are N30 from the CDR1α, D99, and S100 from
the CDR3α, and G97, L98, A99, G100, G101 from the CDR3β.
The most important contribution to ∆∆G (1.26 kcal/mol)
arises from the difference in interactions with the MHC. This is due
to a conformational change that takes place in the Tax P6 region
upon TCR engagement. In the Tax system, the cost of this con-
formational change is balanced by a very favorable interaction of
the Pro ring with hydrophobic residues of the MHC groove, which
does not take place with the shorter Ala side-chain. This is an exam-
ple of how a conformational change taking place along the physical
binding pathways translates into a free energy contribution along
the alchemical pathways.
Overall, it emerges that the total binding free energy difference
between the wild-type and the mutant peptide consists of four
contributions that are similar in magnitude. The self-interaction
of the peptide and the change in the interaction between the pep-
tide and the three portions of its environment (TCR, HLA-A2, and
solvent) all contribute between 0.5 and 1.2 kcal/mol to stabiliz-
ing the wild-type complex. This important result was not evident
from the X-ray structures or the experimental data. Interestingly,
these calculations show that accurate free energy differences could
be obtained although most of the complexity of this system was
ignored in our relatively short simulations including only the
mutated side-chain and its local environment.
ASSESSING THE APPLICABILITY OF THE JARZYNSKI IDENTITY TO
CALCULATE TCR-pMHC BINDING FREE ENERGY PROFILES
In classical thermodynamics, the dissipative work WA→B needed
to bring a system from state A to state B is greater than the free
energy difference ∆GAB between the two states, with equality
only in adiabatic conditions. Conversely, a recent result in non-
equilibrium statistical mechanics, the Jarzynski identity (JI) states
that (66, 67)
e−β∆GAB =
〈
e−βWA→B
〉
0
.
Here, β = (kBT )−1 , with T the temperature and kB the
Boltzmann constant. The average 〈·〉0 is taken over canonically
distributed initial conditions in state A. The JI was proven to hold
in the case of thermostated molecular dynamics (66–69). The JI
was applied with some success to simulations of small molecular
systems (68–71). Given the biological importance of the TCR-
pMHC system, we were compelled to determine if the JI could be
employed to calculate protein–protein binding free energy pro-
files from SMD trajectories of large protein–protein complexes
(72). The free energy profile, or potential of mean force (PMF), is
very relevant because in addition to the total binding free energy
it provides estimates of kon and koff from the free energy barrier
height.
In SMD, an external potential of the form u(ξ(r), t ) is used
to steer the system from position A at time 0 to B at time t
along the reaction coordinate ξ. This potential can be a simple
harmonic potential or take a more complex form such as in the
individual pulling scheme (72) presented in Section “Investigating
TCR-pMHC Interactions Using Steered MD Simulations.” If we
are interested in the PMF along ξ, the JI can be written as (73),
e−βG(ξ)α
〈
δ[ξ(r)− ξ]e−βW (t )
〉
0
.
Importantly, W (t ) is the work accumulated by the perturbed
system (including u), defined as (74),
W (t ) =
∫ t
0
dt
∂u
∂t
(ξ (r) , t ) .
For each of the Tax-A6 and P6A-A6 complexes, we performed
150 trajectories starting from independent conformation of the
bound complex. The TCR and pMHC centers of mass separation
was increased by 2 nm over 4 ns. The resulting work profiles are
shown on Figure 9A and the distribution of final work values is
shown on Figure 9B. As expected if the system is not too far from
equilibrium (71, 75), the distribution (in its central part) close to
a Gaussian. To obtain the PMF, the work profiles W (t ) collected
from multiple SMD simulations have to be postprocessed with
three distinct operations:
1. Reduce from the biased system to the physical system (unbias);
2. Average over all ξ(r) visited during the evolution to recover
G(ξ);
3. Estimate the exponential average
〈
e−βW
〉
0 .
Operations 1 and 2 are performed within a modified weighted
histogram scheme (73) adapted to the case of the individual poten-
tials (72). Operation 3 can be more problematic. If we apply direct
exponential averaging, the estimated PMF is very close to the low-
est measured work profile at a given ξ. In the case where the true
free energy value lies in the unsampled lower tail of the work dis-
tribution, direct averaging will result in a large overestimation.
Indeed, for the Tax-A6 complex, the work profiles of Figure 9A
would result in a dissociation free energy around 250 kJ/mol,
compared to the experimental value of 32.2 kJ/mol (18).
Instead of direct averaging, if we assume that the work dis-
tribution is Gaussian, we can estimate G(ξ) with a second-order
cumulant expansion (71, 75),
G(ξ) = W¯ (ξ)− β
2
σ2 (ξ) .
Here, W¯ (ξ) is the mean and σ the standard deviation of the
work values at ξ obtained by applying operations 1 and 2 above
to each trajectory independently. The resulting PMFs are shown
on Figure 9C. The final dissociation free energies are −110 and
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FIGURE 9 | Application of the Jarzynski identity toTCR-pMHC
dissociation. (A) Work profiles collected in 152 independent trajectories
for the Tax-P6A complex. (B) Histogram of the work distribution at
ξ=2 nm, with a fitted Gaussian distribution. (C) Free energy profiles
calculated using the Jarzynski identity and the cumulant expansion
method.
−210 kJ/mol for Tax-A6 and P6A-A6, respectively, which is a
severe underestimation of the experimental values of 32.5 and
22.5 kJ/mol. We note that the calculated values should be cor-
rected for translational and rotational entropic contributions to
be compared to standard state free energy measurements, but this
does not improve the results.
Our results show that direct averaging produces a strong over-
estimation of G(ξ), which could be fixed only by sampling an
extremely large number of trajectories to get enough low work
values. Conversely, the cumulant expansion produces a strong
underestimation of G(ξ), which shows that the real work dis-
tribution has a shorter lower tail than the Gaussian distribution.
Repeating the calculations with datasets of similar sizes and slightly
different conditions showed the reproducibility of these findings.
Overall, this example illustrates the severe sampling difficulties
that hamper the application of the JI to systems with sizeable dissi-
pation. These difficulties have been evidenced by other researchers
in systematic convergence studies of the JI method (76–79).
ESTIMATION OF RESIDUE CONTRIBUTION TO THE BINDING FREE
ENERGY OF THE TCR/pMHC ASSOCIATION USING MM-PB(GB)SA
In the Molecular Mechanics – Poisson Boltzman Surface Area
(MM-PBSA), or its variant the MM-GBSA, the binding free energy,
∆Gbind, is written as the sum of the gas phase contribution,
∆H
gas
bind, the desolvation free energy of the system upon binding,
∆Gdesolv, and an entropic contribution,−T∆S (80):
∆Gbind = ∆H gasbind +∆Gdesolv − T∆S.
The term ∆H
gas
bind is constituted by the van der Waals (∆H vdw)
and electrostatic (∆H elec) interaction energies between the two
partners in the complex, and their conformational energy change
upon binding,∆H intra:
∆H
gas
bind = ∆Helec +∆GvdW +∆Hintra.
∆Gdesolv is the difference between the solvation free energy,
∆Gsolv, of the complex and that of the isolated parts. ∆Gsolv
is divided into the electrostatic, ∆Gelec, solv, and the non-polar,
∆Gnp, solv, contributions,
∆Gsolv = ∆Gelec,solv +∆Gnp,solv.
∆Gelec, solv is calculated by solving the exact Poisson or the
Poisson–Boltzmann (PB) equation (81, 82) in MM-PBSA, and the
much faster but approximate Generalized Born (GB) model (83)
in MM-GBSA (84). The term ∆Gnp,solv, which can be considered
as the sum of a cavity term and a solute–solvent van der Waals term,
is assumed to be proportional to the solvent accessible surface area
(SASA) (85),
∆Gnp,solv = γSASA + b.
The entropy term can be decomposed into translational, Strans,
rotational, Srot, and vibrational Svib, contributions. These terms
are calculated using standard equations of statistical mechanics
(54, 86).
In the standard MM-PB(GB)SA protocol, all these energy terms
are typically averaged over several hundreds of frames extracted
from multi-nanosecond MD simulation trajectories,generally per-
formed in explicit solvent. Those explicit water molecules are
removed prior to energy calculations. In principle, three trajec-
tories should be performed, one for the complex and one for each
of the isolated partners, and the energy terms calculated using the
corresponding simulation. However, a frequent, less computation-
ally demanding, approximation consists in performing only one
MD simulation for the complex (54). The terms relative to one
isolated partner are then calculated after removing the atoms of
the other partner in the frames extracted from the MD simula-
tion of the complex. In this variant, the conformational energy
change upon association is therefore neglected (∆H intra= 0), and
the influence of conformational changes on the other energy terms
are not captured.
MM-PB(GB)SA has been used successfully to identify the hot-
spots of protein–protein association and to determine the effect of
mutations on association processes (84, 87–90). Two approaches
can be considered. The computational alanine scanning (CAS)
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approach (91) is directly comparable to its experimental coun-
terpart. In this approach, ∆Gbind values are calculated for the
wild-type system, as well as for several mutants in which one
residue has been replaced by an alanine. The difference in ∆Gbind
between the wild-type system and the mutants can be used to
estimate the role played by each residue in the association process.
Alternatively, it is possible to perform a binding free energy decom-
position (BFED) for the wild-type system (84). In this approach,
the contributions to ∆Gbind arising from groups of atoms, typi-
cally single residues, or even backbone or side-chain, are estimated
from the wild-type system by performing a pairwise decomposi-
tion of the MM-PB(GB)SA terms (88, 90). BFED, which requires
only one binding free energy calculation, is faster than CAS. In
addition, BFED provides the possibility to study contributions
from non-mutable groups of atoms, such as the backbone. How-
ever, contrarily to CAS, BFED results cannot be compared directly
to an experimental alanine scanning.
To assess the ability of the MM-GBSA approach to identify
quantitatively the hot-spots residues for the TCR/pMHC associ-
ation, we performed a study of the 2C TCR/SIYR/H-2Kb system
using both the CAS and BFED methods (90). This system was cho-
sen because both the experimental 3D-structure and the results of
an experimental alanine scanning were available at that time (92).
A very good correlation was found between the residue contribu-
tions to ∆Gbind from both methods, with a correlation coefficient
of 0.94, highlighting the interest in the faster BFED approach. A
correlation coefficient of R= 0.67 was found between experimen-
tally determined activity differences for alanine mutants and the
calculated binding free energy changes upon mutation.
Our results also showed that BFED provided a more detailed
and reliable description of the interactions between the TCR
and pMHC molecules when including entropic terms. When the
entropy was taken into account, the correlation coefficient was
increased to 0.72. It was noticeable that the correlation obtained
when neglecting the entropy term, which is very computation-
ally expensive to calculate, was sufficient to quantify and rank
the importance of the residues for TCR/pMHC association. Alto-
gether, these pioneering results suggested that the BFED for
the TCR-pMHC system provides a detailed and reliable enough
description of the interactions between the molecules to be used
as an in silico investigation tool in TCR protein-engineering.
COMPUTER-AIDED PROTEIN ENGINEERING
BACKGROUND
Patients with diverse types of cancer develop tumor-specific CD4+
and CD8+ T cell responses. Although these responses are typically
unable to contain solid tumor growth or hematological malig-
nancies, clinical studies have revealed the adoptive transfer of ex
vivo expanded autologous tumor-specific T cells to be a promising
immunotherapeutic approach to cancer treatment (13). A limita-
tion, however, is that TCRs which bind tumor associated/self anti-
gen are often of relatively low affinity. TCRs generally bind pMHC
in the range of K D= 1–100µM (93). However, as a result of the
thymic negative selection whereby T cells with high-affinity TCRs
for “self” antigens are eliminated to prevent autoimmunity, TCRs
specific for “self” tumor associated antigens tend to be weaker-
binders compared to TCRs specific for “non-self” peptides (94).
Thus, the development of tumor-targeting TCRs to endow them
with optimal binding properties, both in terms of fine-specificity
against the targeted pMHC, and kinetic/affinity parameters that
confer maximum cellular responsiveness, is a field of intense
research toward cancer immunotherapy development (95).
The relative importance of the roles played by the TCR/pMHC
binding affinity (K D), and individual kinetic parameters (kon and
koff), on T cell activation, has been intensively studied recently
(11). The emerging consensus hypothesizes the existence of a
TCR/pMHC “dwell-time”(96) enabling the sequential interaction
of TCRs with a rare antigenic pMHC complex – a process known
as “serial triggering” – and conferring an optimal T cell activa-
tion (97). It has also been demonstrated that both kon and koff
define the “effective half-life” of a TCR/pMHC interaction (98).
Thus, K D, kon, and koff do all contribute to T cell activation and
their optimizations should be addressed concomitantly by TCR
engineering techniques for cancer immunotherapy.
As introduced earlier, TCRs contact pMHC antigens via the
six CDRs (Figure 2), with CDR3α and CDR3β mainly bound
over the peptide, and CDR1 and CDR2, α and β, making more
contacts with MHC. It could thus be expected that mutations of
CDR3s would be more likely to maintain peptide specificity than
mutants of CDR1s and CDR2s. Indeed, several mutagenesis stud-
ies produced high-affinity TCRs bearing mutations on CDR3α and
CDR3β that were found to be peptide-specific (99–102). However,
other studies also discovered high-affinity mutants in CDR1 and
CDR2 retaining peptide specificity despite the close proximity of
the mutated region to MHC residues (99, 103). This indicates
that all six CDRs can serve as a focus for mutagenesis to generate
higher-affinity TCRs, while still potentially retaining substantial
peptide specificity (2, 93).
Several efforts have been performed to optimize TCRs (93),
which mainly consist in experimental yeast (100, 101, 104–106),
phage (18, 102, 103, 107), and mammalian cell (108, 109) display
techniques. These approaches were able to increase the affinity of
the TCR by a factor of 100–106, leading to K D as low as 26 pM
(102). Although very efficient to increase the K D, these techniques
lead to TCRs bearing multiple mutations, without providing a
straightforward control of the effect of each one. Such TCRs are
prone to alloreactivity due to peptide-independent binding of
MHCs (95, 110).
Detailed control of the effect of each mutation at the atomic
level can be provided by in silico rational protein-engineering tech-
niques (111–115). Recently, Haidar et al. (116) engineered the
human A6 TCR for enhanced affinity toward the Tax peptide/HLA-
A2 MHC complex. Rapidly, the authors created a set of 219 fitted
scoring functions, aiming to reproduce the binding affinity change
upon 648 mutations of the ovomucoid turkey inhibitor mole-
cule, using energy and statistically derived potential terms. Each
function was then tested against the affinity changes of a first set
of 11 A6 TCR mutants, and evaluated by correlation. The func-
tion reproducing the best the affinity changes on A6 TCR (named
ZAFFI score) was retained to suggest new mutations. Due to the
significant number of non-binding mutations generated using
only the ZAFFI score, the authors further developed the ZAFFI fil-
ter function. The latter, trained by a Monte Carlo method on the 36
first A6 TCR point mutations, was employed to filter out mutations
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with potentially bad electrostatic contacts. In total 59 mutants were
tested. Twelve were found to be better binders than the wild-type
TCR, as measured experimentally by Surface Plasmon resonance
(SPR). It must be noted that some non-binders were generated
on purpose to help training the ZAFFI score and filter. All muta-
tions found in this study to increase the binding were hydrophobic
substitutions that enhanced the interface complementarity. No
mutation introducing new significant electrostatic contacts, and
thus potentially increasing the selectivity of the TCR/pMHC bind-
ing, was found positive. Despite the use of fitted scoring function
and filter that hampers its straightforward translation to non-TCR
systems, this interesting study illustrated the feasibility of a rational
in silico approach to design TCR with higher affinities. It opened
the road to new approaches, with physically sound and non-fitted
universal free energy estimates, straightforward transferability, and
high success rates.
METHODOLOGY AND RESULTS ON BC1 TCR
Encouraged by the results of our BFED method in reproducing the
outcome of a alanine scanning experiment on the TCR/SIYR/H-
2Kb system (90), we decided to develop a new structure-based
approach, based on MM-GBSA free energy calculations, to ratio-
nally design new TCR sequences. Our approach can be divided into
several steps. First, the importance of each wild-type TCR residue
for the TCR/pMHC association is estimated using a MM-GBSA
BFED. Then, based on the TCR-pMHC structure and the residue
contributions to the binding, mutations are designed for the
residues showing the most promising opportunities of enhance-
ment for the interaction with the pMHC. These putative sequence
modifications are finally selected for experimental testing based
on the estimated binding free energy gain, ∆∆Gbind. The latter
was obtained by calculating the contribution of each residue to
the binding free energy change upon a given mutation,∆∆Gresbind,
as the difference between the residue contribution for the mutated
complex,∆Gres,mutbind , and that for the wild-type complex,∆G
res
bind:
∆∆Gresbind = ∆Gres,mutbind −∆Gresbind.
∆Gresbind and ∆G
res,mut
bind values were calculated from MD sim-
ulations of the wild-type and the corresponding mutated TCR-
pMHC, respectively. The binding free energy difference upon a
given mutation, ∆∆Gbind, was finally obtained by summing the
∆∆Gresbind values over the mutated residue and all the residues in
contact with it. This local summation was preferred to a sum-
mation over all residues of the TCR-pMHC complex since it
suppresses the errors arising from residues far from the site of
the sequence modification, and making no contribution to the
mutation effect.
We have applied our computer-aided protein-engineering
approach to the BC1 TCR (26, 117). This TCR was discovered from
a long-surviving melanoma patient (LAU #155) with a naturally
occurring CD8+ T cell response against the immunodominant
cancer-testis epitope NY-ESO-1157–165 (SLLMWITQC), presented
by the commonly expressed MHC class I allele HLA-A∗0201.
The expression profile of NY-ESO-1 makes it an attractive tar-
get for cancer immunotherapy. It is indeed expressed by several
solid tumors, including melanoma, as well as hematological malig-
nancies (myelomas, lymphomas, and leukemias), while in normal
tissue its expression is limited to the testis cells (118–122). Interest-
ingly, recent studies have shown that an immune response against
NY-ESO-1 can convey an important clinical benefit for the patient.
Seventy-seven percent of patients treated with the CTLA-4 block-
ing antibody ipilimumab showed favorable clinical outcome if they
had a detectable CD8+ T cell responses against NY-ESO-1, com-
pared to only 14% otherwise (123). Our in silico approach was
facilitated by the existence of the crystal structure of the 1G4 TCR
bound to NY-ESO-1/HLA-A∗201 (124), PDB ID 2BNR, available
in the protein databank (125). The sequence of the latter dif-
fers only from that of the BC1 TCR by four residues: Thr95α,
Ser96α, Asn97β, and Thr98β of the 1G4 TCR, are replaced by
Gln95α, Thr96 α, Ala97β, and Ala98β in BC1 TCR, respectively.
These sequence modifications were introduced in the 1G4 X-ray
structure before applying our approach. Noticeably, three crys-
tal structures of free and bound 1G4 TCR were solved after we
performed our simulations (126). These affinity-enhanced TCRs
contain mutations in the CDR3 loops or in both the CDR2 and
CDR3 loops, which were obtained by in vitro directed evolution
(102). They revealed that the binding mode for the high-affinity
TCRs was identical to that of the wild-type TCR, with only limited
changes in the mutated CDRs. A previous assessment by Zhao et
al., of six phage library-derived 1G4 TCR variants demonstrated
three categories of TCR specificity related to affinity; (i) super-
high-affinity TCR (26 pM) which completely lacked specificity,
(ii), mid-range affinity TCR (5 and 85 nM) that were specific only
in the absence of CD8 co-engagement, and, (iii), intermediate-
range affinity TCR (0.4 and 4µM) that maintained specificity
(107). By taking a rational computer-aided approach to TCR
engineering, we were able to design a new original set of TCR
variants. We enhanced the TCR/pMHC binding interactions in a
“step-by-step” manner, targeting change to specific kinetic para-
meters, and limiting overall gain in affinity as well as potential for
cross-reactivity.
Twenty four of the most promising mutations identified using
this approach, spanning 11 different residues of the CDRs (see
Figure 10), were introduced into the BC1 TCR sequence. The engi-
neered proteins were produced using a mammalian cell expression
system, purified and tested by titration ELISA. We found a quali-
tative agreement between the calculated ∆∆Gbind values and the
experimental results. Thirteen (54%) of the mutations proposed
by our approach showed improved affinity for the pMHC, com-
pared to the wild-type TCR (Zoete et al., in preparation). We
obtained an excellent correlation of R= 0.85 between the calcu-
lated∆∆Gbind and the measured co-logarithm of the optical den-
sity measured by ELISA titration. Only three outliers were found:
Vβ A51V, Y94N, and A51D. Their presence might be explained by
conformational rearrangements upon mutation, minimally acces-
sible during the MD simulations. This correlation illustrates the
efficiency with which the ∆∆Gbind calculated with our method
allows for the rational selection of TCR sequence modifications
potentially increasing its affinity for pMHC.
For quantitative TCR/pMHC binding measurements some
of the TCRs were refolded from bacterial inclusion bod-
ies and analyzed by SPR. We began by producing TCR
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FIGURE 10 | Location of the BC1TCR residues for which sequence
modifications were designed. TCRα and β are shown as blue and cyan
surfaces. Modified residues are colored in red. The NY-ESO-1 peptide is
shown in ball and stick and the MHC as a transparent ribbon. Only the α1
and α2 helices of MHC are displayed, for the clarity of the figure.
having one amino acid change. The best single replace-
ment TCR had 52-fold improvement in K D (Zoete et al.,
in preparation). Then, we gradually increased affinity by
step-wise combination of rationally selected replacements in
both the β-chain and the α-chain. As predicted by model-
ing and assessed by SPR binding assays, we found the fol-
lowing progression in K D (Table 1): WT (21.4µM)> β-G50A
(4.6µM)> β- G50A+A51E (1.9µM)> β-G50A+A51E+A97L
(0.91µM)> β-G50A+ βA51E-βA97L+ α-S53W (0.14µM)
(Zoete et al., in preparation) (7). Our method thus allows for the
design of TCRs with fine tuned K D values, potentially leading to T
cells with optimal activity (7). This is in contrast with experimental
display approaches which tend to select the tightest-binding TCRs
that can potentially surpass an “affinity threshold of specificity,” as
has been reported for the 1G4 TCR (107). We found a very satisfy-
ing correlation between the calculated energies and the pK D and
koff values measured by SPR (Zoete et al., in preparation).
Importantly, we found that our approach was able to pre-
dict successfully mutations toward both non-polar and polar
residues, contrary to previous studies where only designed muta-
tions toward non-polar residues were successful in increasing the
experimental affinity (116). To take place, polar interactions, such
as hydrogen bond or ionic interaction, require an appropriate
match of chemical functionalities and precise geometrical con-
strains between interacting partners. Therefore, they provide an
essential contribution to the directionality and the specificity of
molecular recognition (127). This point is critical to the devel-
opment of TCRs for immunotherapies. It is indeed essential that
TCRs maintain their specificity, and do not acquire novel antigen
specificities that might cause off-target toxicity upon the adoptive
transfer of genetically engineered T cells to patients. Two ratio-
nally designed sequence modifications provide interesting exam-
ples regarding the detailed control provided by our approach on
the binding process. Mutation β-A51E introduces an ionic inter-
action between the new glutamate side-chain and MHC Arg75
Table 1 | Binding affinity of rationally designed BC1TCR variants [from
Ref. (7)] measured by SPR.
TCR mutations KD (µM)
β-V49I Near non-binding
Wild-type 21.4
β-G50A 4.62
β-A97L 2.69
β-G50A+A51E 1.91
β-G50A+A51E+A97L 0.91
α-S53W+ β-G50A+A51E 0.4
α-S53W+ β-G50A+A51E+A97L 0.14
β-G50A+A51I+G52Q+ I53T 0.015
(Figure 11A), translating into a calculated favorable ∆∆Gbind.
This replacement produced a fourfold experimental improvement
in K D as measured by SPR (8). This mutation thus increases the
affinity for the pMHC through better interactions with the MHC
molecule, and therefore cannot be expected to increase the selec-
tivity for the peptide antigen. Interestingly, we also designed the
β-A97D variant, which introduces a new hydrogen bond between
TCR and the peptide Thr7 side-chain (Figure 11B). The overall
effect of this modification was somewhat unfavorable to the bind-
ing, as shown by the experimental titration ELISA and calculated
∆∆Gbind values (Zoete et al., in preparation). However, despite
the decreased activity, this mutation is interesting for the puta-
tive gain in selectivity for the NY-ESO-1 system thanks to the new
polar interaction taking place between the TCR and the peptide.
An experimental alanine scanning of the peptide supported this
idea. The affinity of several TCR mutants (β-G50A/A51E, A97L,
A97D, I53W, V95L, and Y94N) for the different mutated pMHC
were measured by titration ELISA and compared to the results for
the wild-type TCR. All mutated TCR showed affinities similar to
the wild-type TCR for all the peptide mutants. The only exception
was the β-A97D TCR mutant, which did not bind to the peptide
T7A mutant contrary to the wild-type TCR. This experimental
result is in good agreement with the in silico data showing that
all those TCR mutations modified the interactions with the MHC
rather than with the peptide with the exception of β-A97D which
exchanges a hydrogen bond with the peptide Thr7 side-chain. The
β-A97L TCR mutant, which makes non-polar contact with the
side-chain of peptide Thr7 but no hydrogen bond, is less affected
by the Thr7 mutation to Ala than the β-A97D TCR variant. Thus,
although the β-A97D modification is somewhat unfavorable to
the binding, it could be useful to introduce it in engineered TCRs
targeting NY-ESO-1, in addition to other variations increasing the
affinity, in order to obtain more selective TCRs.
The selectivity of TCRs designed by our approach was tested
experimentally. We observed no interaction of our TCRs with any
non-cognate pMHC complexes. In addition, tetramer binding
studies with an extensive panel of non-cognate pMHC revealed
that the TCR variants expressed at the cell-surface were also
HLA-A∗0201/NY-ESO-1157–165 –specific (7).
The binding free energy calculations used in our approach
are physics-based and not reliant on ad hoc model fitting. We
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FIGURE 11 | Interaction between pMHC and the modified residues of
the β-A51E (A) and β-A97DTCR variants (B). TCR wild-type residues are
shown in ball and stick, colored according to the atom types. Modified
residues are colored in magenta. New hydrogen bonds are shown as dotted
blue lines.
can thus expect that our design strategy is highly transferable to
any protein/protein interaction of known structure and biological
interest.
INTERMEDIATE TCR/pMHC BINDING PARAMETERS CONFER MAXIMUM
BIOLOGICAL RESPONSES
In order to efficiently screen our extensive panel of modeled
BC1 TCR variants we began by establishing a mammalian cell
expression system for TCR production. HEK-293 cells were PEI co-
transfected with pHYK8 plasmids encoding the α- and β-chains,
each under control of the CMV promoter. Following the strat-
egy of Chang et al. an acidic-basic zipper was incorporated to
facilitate heterodimeric chain pairing (128). Following 5–7 days
culture in serum-free medium, the TCR variants were HIS-tag
purified from the supernatants (yields were up to ∼3 mg/L) and
compared to the wild-type TCR by titration ELISA for binding
plate-captured pMHC. Single and multiple amino acid replace-
ments were assessed in the α- and β-chains. Over 60% showed
enhanced pMHC binding as compared to the wild-type TCR.
Further, binding of the TCR variants against an Ala replacement
scan of the NY-ESO-1157–165 peptide (SLLMWITQC) revealed
near identical patterns of recognition, suggesting a conserved
mechanism of binding. For all TCR variants, M160, W161, I162,
and Q164 were critical contact residues as their replacement with
Ala abolished TCR/pMHC binding (7, 8).
The TCR chains were subcloned into pGMT7 for their expres-
sion as inclusion bodies in BL21(DE3)pLys bacterial cells and
subsequent TCR refolding by dialysis (129). The binding affinity
and kinetics for a panel of TCRs having various combinations of
amino acid replacements in CDR2-β, CDR3-β, and CDR2-α, were
measured by SPR using the BIACore 3000. Most natural TCRs
bind pMHC with weak affinity, in the range of 1–100µM, as a
result of slow association (103–104 M−1s−1), and fast rates of dis-
sociation (typically a half-life of seconds at 37°C) (1, 10, 130),
reflecting the need for T lymphocytes to detect a virtually limitless
repertoire of foreign epitopes while avoiding autoreactivity, and
the fact that they do not undergo somatic hypermutation as do
antibodies. The eight TCRs chosen amongst our panel incremen-
tally increased in affinity from 21.4µM for the wild-type one, to
extreme physiologic affinity at 15 nM (summarized in Table 1).
Lentiviral constructs were built to assess the activity of the ratio-
nally designed TCRs in transduced primary human CD8+ T cells
and identify those able to confer maximum activity levels. A range
of functions were assessed for the transduced CD8+ T cells includ-
ing Ca2+ flux, intracellular signaling, cell-surface TCR clustering,
target-cell killing, and cytokine/chemokine release. All activity lev-
els for affinity-enhanced TCRs uniformly increased from that of
the wild-type TCR, reaching a peak for TCRs within the upper
range of natural affinity, 1–5µM. Beyond this affinity, in the supra-
physiological range, however, activity levels began to drop, both in
the presence and absence of CD8 co-receptor engagement, usually
reaching a minimum for the extreme supraphysiological affinity
TCR (1, 7, 8, 10, 130). However, under experimental conditions in
which the T cells were exposed to target-cells pulsed with high con-
centration of NY-ESO-1157–165 peptide this attenuation in activity
for the supraphysiological affinity TCR was no longer observed.
This phenomenon is illustrated in Figure 12. Importantly, no non-
specific reactivity was observed for any of the rationally designed
TCRs (7, 8).
Over the years two main models of T cell activation have
emerged [reviewed in Stone et al. (11)]. For the “affinity model”
(101, 131) the total number of TCRs bound to pMHCs at equi-
librium is thought to regulate T cell activity levels. The “half-life
model” proposes that the TCR must stay bound with sufficiently
strength/duration for productive signaling and also enable the ser-
ial engagement of the “rare” antigenic pMHC complex by adjacent
TCR for the amplification of signal (i.e., the TCRs must have an
optimal dwell-time) (96, 97, 132–134). Although the half-life of
a TCR/pMHC interaction has traditionally been calculated from
koff values (t 1/2= ln2/koff), recent work by Aleksic et al. has ele-
gantly demonstrated that for TCRs having faster association rates
there can be rapid TCR/pMHC re-engagement rather than a lateral
diffusion of TCRs in the cell membrane to prolong the effective
half-life of the TCR/pMHC interaction. Thus, both koff and kon
can contribute to TCR/pMHC dwell or confinement time (135).
Overall our findings correspond to the “half-life” model of T cell
activation. Presumably the supraphysiological affinity TCRs are
limiting the serial engagement but at high peptide concentrations
this is not an issue as the TCR can find more pMHC molecules
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FIGURE 12 | Sketch ofT cell activity as a function ofTCR-pMHC affinity.
At low to intermediate levels of pMHC, T-cell activity is optimal for TCR
within K D range 1–5µM (orange curve). At high levels of pMHC T-cell
activity is not attenuated for supraphysiologic affinity TCR (purple curve).
on the target-cell-surface. This is demonstrated in Figure 13. Our
work also demonstrated the value of a modeling approach because
TCRs with particular binding parameters, i.e., falling within an
optimal affinity range, either through faster on-rates or slower
off-rates, can be developed to enable maximum T cell activity
levels.
CONCLUSION
We found that the synergy between in silico design, and in vitro
testing using both soluble molecules and transfected cells is key to
the design of improved TCRs to be used in adoptive cell transfer
therapies. Using an innovative structural approach based on recent
in silico techniques, we have developed a method to rationally opti-
mize the surface of the TCR to increase its affinity for pMHC. As
opposed to library screening, we propose a step-wise, incremen-
tal optimization of the TCR. This allows the preservation of the
favorable initial properties of the TCR through the various cycles.
Our optimization method can selectively target contacts involv-
ing the MHC or the peptide, thus maintaining a good balance
between overall affinity and specificity. In addition, modifying
only a few amino acids reduces the risk of obtaining undesired
cross-recognition or raising anti-TCR antibodies in vivo. This
rational optimization approach is therefore very promising to
the design of TCRs for adoptive T cell immunotherapy clinical
trials.
The application of our TCR engineering approach to the
tumor-targeting BC1 TCR targeted to the A2/NY-ESO-1157–165
antigen identified several original single mutations of the CDR
loops conferring increased experimental affinity for pMHC com-
pared to the wild-type TCR. T cells expressing some of the affinity-
enhanced TCR showed better overall functionality, including
improved killing of both peptide-loaded T2 cells and melanoma
FIGURE 13 |T-cell activation in the presence of limiting (A) or
saturating levels (B) of target pMHC complex. In the case where target
pMHC concentration is limiting, TCRs of too high-affinity may inhibit serial
engagement and thereby attenuate T-cell activity levels. MHCs are colored
in light brown, β2-microglobulins in dark brown, TCRs in blue and peptide
antigens are shown as small green, red, and yellow circles. The peptide
colored in red corresponds to the specific antigen.
tumor cell lines, higher proliferative capacity, and increased levels
of cytokine/chemokine secretion, as compared to wild-type TCR
expressing T cells. For all functional assays, we observed a gain in
CD8+ T cell activity level with increase in affinity, with a peak at
an affinity of ∼1–5µM. Beyond this affinity we observed a pro-
gressive decrease in activity levels. We are currently testing the
relative activity of the different TCRs in vivo in a mouse model.
The successful candidates are planned to enter a phase I clinical
trial program for stage IV melanoma. As the methods presented
here are general and transferable to any TCR-pMHC complex,
other cancer types will follow shortly.
In parallel to direct applications of the existing approach,
we will take advantage of the methodological work presented
above to improve our in silico TCR optimization method. The
development of homology-based approaches to model the 3D-
structure of TCR-pMHC complexes potentially extends the use
of our method to TCR repertoires for which no X-ray structure
is available. The detailed picture of the TCR/pMHC interaction
emerging from the MD simulations showed the presence of sin-
gle water molecules trapped at the interface (20). Including these
interfacial waters in the BFED scheme would improve accuracy in
some cases. Close residues at protein–protein interfaces can dis-
play collaborative effects that result in the non-additivity of their
contributions to the binding free energy, which will have to be
taken into account in the next generation of TCR optimization
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methods. Noticeably, because the binding free energy decomposi-
tion method used is physics-based, without any ad hoc parameters,
our in silico techniques are straightforwardly transferable to other
types of macromolecular protein complexes.
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